You are here: Home: LCU 3 | 2006 : Mark A Socinski, MD: Select publications

SELECT PUBLICATIONS

Gandara DR et al. Long-term survival in stage IIIb non-small cell lung cancer (NSCLC) treated with consolidation docetaxel following concurrent chemoradiotherapy (SWOG S9504). Proc ASCO 2005;Abstract 7059.

Gandara DR et al. Consolidation docetaxel after concurrent chemoradiotherapy in Stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003;21(10):2004-10. Abstract

Gatzemeier U et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc ASCO 2004;Abstract 7010.

Giaccone G et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial — INTACT 1. J Clin Oncol 2004;22(5):777-84. Abstract

Gradishar WJ et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-803. Abstract

Herbst RS et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non–small-cell lung cancer. J Clin Oncol 2005a;23(11):2544-55. Abstract

Herbst RS et al; TRIBUTE Investigator Group. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005b;23(25):5892-9. Abstract

Herbst R et al. ZD6474 plus docetaxel in patients with previously treated NSCLC: Results of a randomized placebo-controlled Phase II trial. Presentation. Proceedings from the 11th World Conference on Lung Cancer 2005c;Abstract O-100.

Herbst RS, Sandler AB. Non-small cell lung cancer and antiangiogenic therapy: What can be expected of bevacizumab? Oncologist 2004;9(Suppl 1):19-26. Abstract

Heymach JV et al. A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel in patients with NSCLC. Proc ASCO 2005;Abstract 3023.

Johnson BE et al. Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC. Proc ASCO 2005;Abstract 7102.

Natale R et al. A comparison of the antitumour efficacy of ZD6474 and gefitinib (Iressa) in patients with NSCLC: Results of a randomized, double-blind Phase II study. Presentation. Proceedings from the 11th World Conference on Lung Cancer 2005;Abstract O-103.

Sandler AB et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599. Presentation. ASCO 2005;Abstract 4.

Shepherd FA et al; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-32. Abstract

Sparreboom A et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 2005;11(11):4136-43. Abstract

Stinchcombe TE et al. Preliminary results of phase I trial of carboplatin (CP) in combination with ABI-007 administered weekly or every 3 weeks in patients (pts) with solid tumors. San Antonio Breast Cancer Symposium 2005;Abstract 1092.

Tsao MS et al. Erlotinib in lung cancer — Molecular and clinical predictors of outcome. N Engl J Med 2005;353(2):133-44. Abstract

Table of Contents

Top of Page